Drug intelligence / Profile preview

GKIND004-5A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules

Overview

GKIND004-5A is a small molecule therapeutic candidate being developed by China Resources Guokang Pharmaceutical for the treatment of fibrotic diseases, specifically idiopathic pulmonary fibrosis (IPF) and liver fibrosis. The drug is designed to modulate pathways associated with the progression of fibrosis, although its specific molecular target has not been publicly disclosed by the sponsor. As of 2024, the program is in the IND-enabling (Pre-IND) stage of development, with the company working toward regulatory filings to initiate clinical trials.

Other names: GKIND004-5AGKIND-004-5AGKIND 004-5A

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on GKIND004-5A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND004-5A.

Explore the full profile